Glycyl H-1152 (hydrochloride)

Glycyl H-1152 hydrochloride (compound 18) is a glycyl derivative of Rho-kinase inhibitors H-1152 dihydrochloride. Glycyl H-1152 hydrochloride inhibits ROCKII, Aurora A, CAMKII and PKG, with IC50s of 0.0118, 2.35, 2.57 and 3.26 μM respectively. Glycyl H-1152 hydrochloride has higher selective than H-1152 hydrochloride[1].

Product Specifications

CAS Number

[913844-45-8]

UNSPSC

12352005

Hazard Statement

H225, H370

Target

Aurora Kinase; CaMK; ROCK

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Cytoskeleton; Epigenetics; Neuronal Signaling; Stem Cell/Wnt; TGF-beta/Smad

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/glycyl-h-1152-hydrochloride.html

Concentration

11.13 mM * 100 μL in Methanol

Purity

99.9

Solubility

10 mM in DMSO

Smiles

O=S(N1[C@@H](C)CN(C(CN)=O)CCC1)(C2=CC=CC3=C2C(C)=CN=C3)=O.[H]Cl.[H]Cl

Molecular Formula

C18H26Cl2N4O3S

Molecular Weight

449.40

Precautions

H225, H370

References & Citations

[1]Tamura M, et, al. Development of specific Rho-kinase inhibitors and their clinical application. Biochim Biophys Acta. 2005 Dec 30; 1754 (1-2) : 245-52.